AYA.AX Artrya Limited (ASX) 23 Feb 2026: A$3.23 close, AI growth outlook
AYA.AX stock closed at A$3.23 on 23 Feb 2026 after trading between A$3.16 and A$3.32. Investors are watching Artrya Limited (AYA.AX, ASX) because its Salix AI product targets coronary artery disease detection. Near-term trading shows mixed momentum but long-term AI adoption could lift revenue if clinical and commercial rollouts scale. This piece breaks down valuation, technicals, Meyka AI grading, and forecast scenarios to help investors assess risk and reward on the ASX in AUD.
AYA.AX stock market snapshot
Artrya Limited (AYA.AX) closed at A$3.23 on the ASX with volume 200,235 shares. The company’s market cap stands at A$373,956,000 and shares outstanding are 113,320,000. Day range was A$3.16–A$3.32 and the 52-week range is A$0.56–A$5.24.
Trading sits below the 50-day average (A$4.03) but above the 200-day average (A$2.43), showing medium-term strength with recent volatility.
AYA.AX stock valuation and financials
Artrya reports EPS -A$0.18 and a negative PE of -18.33. Price-to-book is 15.97, well above the healthcare peer average PB 3.98, reflecting investor expectations for AI-driven growth rather than current earnings. Key liquidity metrics include a current ratio 8.27 and cash per share A$0.11.
Revenue per share is minimal at A$0.00 and operating cash flow per share is negative A$-0.14. High R&D spending (R&D to revenue 197.50%) compresses margins today but supports product development.
AYA.AX stock product, market and sector context
Artrya sells the Salix AI platform for coronary CT angiography automation. If clinical acceptance and hospital procurement scale, addressable revenue could expand in diagnostic imaging. The healthcare sector on ASX shows average PE 27.73 and PB 3.98, placing Artrya as a high-valuation growth play rather than a value name.
Clinical validation milestones and hospital contracts will drive the next re-rating. For background on the company profile see source.
AYA.AX stock technicals and trading signals
Momentum indicators are mixed: RSI 40.82 (mildly weak) and MACD histogram near -0.01. Trend strength reads ADX 29.44, suggesting a developing trend. Bollinger bands sit at Upper A$4.09 / Middle A$3.49 / Lower A$2.88, signalling a neutral-to-wider volatility window.
Volume remains below the 90-day average, with avgVolume 682,885. Low liquidity spikes can magnify price moves, so watch intraday volume if catalysts appear.
Meyka AI grade, forecast and price targets for AYA.AX stock
Meyka AI rates AYA.AX with a score of 63.36 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating highlights growth potential balanced by weak short-term earnings and elevated valuation.
Meyka AI’s forecast model projects Monthly A$3.09, Quarterly A$5.03, and Yearly A$7.83. Compared with the current price A$3.23, the model implies a -4.33% move to the monthly level, +55.73% to the quarterly level, and +142.20% to the yearly level. Forecasts are model-based projections and not guarantees. Scenario price targets: conservative A$4.50 and bull A$8.00, with corresponding implied upsides of +39.32% and +147.68%.
AYA.AX stock risks and catalysts
Primary catalysts include commercial contracts, regulatory approvals, and successful hospital rollouts for Salix. Positive clinical studies or partnerships could lift sentiment quickly. Risks include continued negative earnings, high R&D burn, and a large price-to-book premium that may re-rate if growth slows.
Investor watchlist items: upcoming earnings announcement on 2026-02-24, changes in monthly volume, and any ASX disclosures on sales or validation studies.
Final Thoughts
AYA.AX stock closed at A$3.23 on 23 Feb 2026 with clear trade-offs between technology potential and present financials. Artrya’s Salix AI gives it a differentiated product in diagnostic imaging, but the company posts negative earnings (EPS -A$0.18) and a high price-to-book (15.97) versus healthcare peers. Meyka AI rates AYA.AX 63.36/100 (Grade B, HOLD), reflecting growth opportunity balanced by execution and valuation risk. Our model shows a near-term monthly projection of A$3.09 and a one-year forecast of A$7.83, implying +142.20% upside to the year target and -4.33% to the monthly level. Those forecasts assume scaling of clinical adoption and improved sales conversion. For risk-managed investors, consider staged exposure around delivery milestones. Remember, forecasts are model-based projections and not guarantees. Meyka AI, our AI-powered market analysis platform, flags catalysts and risks but does not provide personalised financial advice
FAQs
What drove AYA.AX stock price today?
AYA.AX stock closed at A$3.23 on 23 Feb 2026. Trading was driven by modest volume and positioning ahead of Artrya’s earnings announcement on 24 Feb 2026 and continued attention on Salix AI commercial progress.
How does Meyka AI view AYA.AX stock?
Meyka AI rates AYA.AX 63.36/100 (Grade B, HOLD). The score balances AI growth potential with weak current earnings and elevated valuation. This grade is informational and not investment advice.
What are realistic price targets for AYA.AX stock?
Scenario targets: a conservative target of A$4.50 (≈+39.32%) and a bull target of A$8.00 (≈+147.68%). These assume successful clinical adoption and commercial scale; results are not guaranteed.
What are the main risks for AYA.AX stock?
Key risks for AYA.AX stock include continued negative EPS (-A$0.18), heavy R&D burn, high PB ratio (15.97), and slow hospital procurement. Regulatory or clinical setbacks would pressure the share price.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.